[{"orgOrder":0,"company":"Aposcience","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"APO-2","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Aposcience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Aposcience \/ FGK Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Aposcience \/ FGK Clinical Research"},{"orgOrder":0,"company":"Omeza","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Podiatry","graph2":"Phase I","graph3":"Omeza","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeza \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeza \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu ProteLight Pharmaceutical & Biotechnology","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Antimicrobial Peptide PL-5","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Jiangsu ProteLight Pharmaceutical & Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Jiangsu ProteLight Pharmaceutical & Biotechnology \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu ProteLight Pharmaceutical & Biotechnology \/ Parexel"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Alira Health","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Skinte","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dermal","sponsorNew":"PolarityTE \/ Alira Health","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Alira Health"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Professional Education and Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Skinte","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dermal","sponsorNew":"PolarityTE \/ Professional Education and Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Professional Education and Research Institute"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SkinTE","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dermal","sponsorNew":"PolarityTE \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Inapplicable"},{"orgOrder":0,"company":"Discovery Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Discovery Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Discovery Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Discovery Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Shandong Qilu Stem Cells Engineering Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Cord Blood Mononuclear Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Shandong Qilu Stem Cells Engineering Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Shandong Qilu Stem Cells Engineering Co., Ltd."},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cytora","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"hOMSC200","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cytora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytora \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytora \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Gunze Medical Limited","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"MiMedx \/ Gunze Medical Limited","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Gunze Medical Limited"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diperoxochloric Acid","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Centaur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Centaur Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centaur Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Best Buy Medical Canada","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Best Buy Medical Canada","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Best Buy Medical Canada"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"BioStem Technologies","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ BioStem Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ BioStem Technologies"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Peptide","year":"2025","type":"Acquisition","leadProduct":"Becaplermin","moa":"Platelet-derived growth factor receptor","graph1":"Podiatry","graph2":"Approved FDF","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"Cathay General Hospital","sponsor":"Oneness Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fespixon","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase IV","graph3":"Cathay General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cathay General Hospital \/ Oneness Biotech","highestDevelopmentStatusID":"11","companyTruncated":"Cathay General Hospital \/ Oneness Biotech"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"China Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fespixon","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase IV","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Oneness Biotech \/ China Medical University Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Oneness Biotech \/ China Medical University Hospital"},{"orgOrder":0,"company":"SerenaGroup, Inc.","sponsor":"Tides Medical","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DLAM","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase IV","graph3":"SerenaGroup, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SerenaGroup, Inc. \/ Tides Medical","highestDevelopmentStatusID":"11","companyTruncated":"SerenaGroup, Inc. \/ Tides Medical"},{"orgOrder":0,"company":"Biotechnology Institute IMASD","sponsor":"Hospital de Basurto","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Plasma Rich In Growth Factors","moa":"Growth factor","graph1":"Podiatry","graph2":"Phase IV","graph3":"Biotechnology Institute IMASD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Biotechnology Institute IMASD \/ Hospital de Basurto","highestDevelopmentStatusID":"11","companyTruncated":"Biotechnology Institute IMASD \/ Hospital de Basurto"},{"orgOrder":0,"company":"MicuRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase III","graph3":"MicuRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx \/ Inapplicable"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioTissue Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Amniox Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Amniox Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amniox Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amniox Medical \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"PainReform","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"PainReform","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PainReform \/ Lotus Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"PainReform \/ Lotus Clinical Research"},{"orgOrder":0,"company":"Cali Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CPL-01","moa":"Na channel-alpha-subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Cali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cali Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cali Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Anterogen Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Inapplicable"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ON101","moa":"Immune","graph1":"Podiatry","graph2":"Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oneness Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Energenesis Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ENERGI-F703","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Energenesis Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Energenesis Biomedical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Energenesis Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Xianglei Tangzu Gao","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II\/ Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oneness Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oneness Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Lavior Pharma Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Lavior","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II\/ Phase III","graph3":"Lavior Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Lavior Pharma Inc. \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lavior Pharma Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Private Placement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0.02,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Lyophilised Powder for Solution","sponsorNew":"Rion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Inapplicable"},{"orgOrder":0,"company":"Technophage, SA","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TP-102","moa":"Enzymes","graph1":"Podiatry","graph2":"Phase II","graph3":"Technophage, SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Technophage, SA \/ VectorB2B","highestDevelopmentStatusID":"8","companyTruncated":"Technophage, SA \/ VectorB2B"},{"orgOrder":0,"company":"Microbion","sponsor":"CUBRC | National Medical Research Council, Singapore | MTEC","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Microbion \/ CUBRC | National Medical Research Council, Singapore | MTEC","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ CUBRC | National Medical Research Council, Singapore | MTEC"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Professional Education and Research Institute | PrimeVigilance Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lakewood-Amedex \/ Professional Education and Research Institute | PrimeVigilance Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Professional Education and Research Institute | PrimeVigilance Ltd"},{"orgOrder":0,"company":"Cali Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CPL-01","moa":"Na channel-alpha-subunit","graph1":"Podiatry","graph2":"Phase II","graph3":"Cali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cali Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cali Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lakewood-Amedex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Inapplicable"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Podiatry","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lakewood-Amedex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0.02,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ CARB-X"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"US Navy","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ US Navy"},{"orgOrder":0,"company":"Rion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Rion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Inapplicable"},{"orgOrder":0,"company":"Srinakharinwirot University","sponsor":"Oxo Chemie | Altermed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"WF10","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Srinakharinwirot University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Srinakharinwirot University \/ Oxo Chemie | Altermed","highestDevelopmentStatusID":"8","companyTruncated":"Srinakharinwirot University \/ Oxo Chemie | Altermed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Anterogen Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Inapplicable"},{"orgOrder":0,"company":"Joseph Boykin, MD","sponsor":"George Mason University | Central Arkansas Veterans Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Folinic Acid Calcium Salt","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Joseph Boykin, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Boykin, MD \/ George Mason University | Central Arkansas Veterans Healthcare System","highestDevelopmentStatusID":"8","companyTruncated":"Joseph Boykin, MD \/ George Mason University | Central Arkansas Veterans Healthcare System"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NGI226","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AUP1602-C","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Aurealis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aurealis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rion","sponsor":"Professional Education and Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Pep Purified Exosome Product","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Rion \/ Professional Education and Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Professional Education and Research Institute"},{"orgOrder":0,"company":"Blue Blood Biotech Corp.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BB-101","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Blue Blood Biotech Corp.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Blood Biotech Corp. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blue Blood Biotech Corp. \/ Inapplicable"},{"orgOrder":0,"company":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MDI-1228","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Murdoch Children\u2019s Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute"},{"orgOrder":0,"company":"Supergenics Life Science Sdn. Bhd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Supergenics Life Science Sdn. Bhd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Supergenics Life Science Sdn. Bhd. \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Supergenics Life Science Sdn. Bhd. \/ Inapplicable"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Xbiome","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"AUP-16","moa":"FGF2","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aurealis Therapeutics \/ Xbiome","highestDevelopmentStatusID":"7","companyTruncated":"Aurealis Therapeutics \/ Xbiome"},{"orgOrder":0,"company":"Technophage, SA","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"TP-102","moa":"Enzymes","graph1":"Podiatry","graph2":"Phase II","graph3":"Technophage, SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Technophage, SA \/ VectorB2B","highestDevelopmentStatusID":"8","companyTruncated":"Technophage, SA \/ VectorB2B"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HTX-034","moa":"COX-2","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"SaNOtize \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SaNOtize \/ Inapplicable"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AUP1602-C","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Aurealis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aurealis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NOxy Health Products","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NOX1416","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"NOxy Health Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"NOxy Health Products \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NOxy Health Products \/ Inapplicable"},{"orgOrder":0,"company":"NOxy Health Products","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NOX1416","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"NOxy Health Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"NOxy Health Products \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NOxy Health Products \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"University of Mississippi Medical Center","sponsor":"Keystone Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Podiatry","graph2":"Phase I","graph3":"University of Mississippi Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Mississippi Medical Center \/ Keystone Pharmacy","highestDevelopmentStatusID":"6","companyTruncated":"University of Mississippi Medical Center \/ Keystone Pharmacy"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CYP-006TK","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Amniotic Chorion Tissue Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"CellResearch Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellResearch Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CellResearch Corporation \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Vitruvian Medical Devices, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Plasma","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Vitruvian Medical Devices, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"Vitruvian Medical Devices, Inc. \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vitruvian Medical Devices, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Cell2Cure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Adipose Tissue Derived Mesenchymal Stromal\/Stem Cell","moa":"Progenitor cell","graph1":"Podiatry","graph2":"Phase I","graph3":"Cell2Cure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cell2Cure \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cell2Cure \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai East Hospital","sponsor":"Faendrich Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Autoregulatory Monocyte","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Shanghai East Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai East Hospital \/ Faendrich Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai East Hospital \/ Faendrich Biotechnology"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"FibroBiologics","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CYWC628","moa":"Undisclosed","graph1":"Podiatry","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ FibroBiologics","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ FibroBiologics"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Podiatry","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Changi General Hospital","sponsor":"ELO Water Pte. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Elo Water","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"Changi General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changi General Hospital \/ ELO Water Pte. Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Changi General Hospital \/ ELO Water Pte. Ltd."},{"orgOrder":0,"company":"Orkla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Podiatry","graph2":"Undisclosed","graph3":"Orkla","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Orkla \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Orkla \/ Inapplicable"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Marine Collagen Peptides","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ON101","moa":"Immune","graph1":"Podiatry","graph2":"Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oneness Biotech \/ Inapplicable"},{"orgOrder":0,"company":"The VA Western New York Healthcare System","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Procenta","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"The VA Western New York Healthcare System","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"The VA Western New York Healthcare System \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The VA Western New York Healthcare System \/ Inapplicable"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"FibroBiologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FibroBiologics \/ Undisclosed"},{"orgOrder":0,"company":"New Horizon Medical Solutions","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Amnio Matrix","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"New Horizon Medical Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New Horizon Medical Solutions \/ Amarex Clinical Research","highestDevelopmentStatusID":"1","companyTruncated":"New Horizon Medical Solutions \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Eluciderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ELU42","moa":"Wnt signalling pathway","graph1":"Podiatry","graph2":"IND Enabling","graph3":"Eluciderm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eluciderm \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Eluciderm \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
